Evidence map›Paper›PMID 38753169›Full record

ArticleCancer immunology, immunotherapy : CII2024

Effect of radiochemotherapy on peripheral immune response in glioblastoma.

Léa Hampe, Susy Daumoine, Emeric Limagne, Nicolas Roussot, François Borsotti, Julie Vincent, Sylvia Ilie, Caroline Truntzer, François Ghiringhelli, Marion Thibaudin

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Léa HampeUniversity Bourgogne Franche-Comté, Dijon, France.
Susy DaumoineUniversity Bourgogne Franche-Comté, Dijon, France.
Emeric LimagneUniversity Bourgogne Franche-Comté, Dijon, France.
Nicolas RoussotUniversity Bourgogne Franche-Comté, Dijon, France.
François BorsottiDepartment of Neurosurgery, University Hospital François Mitterrand, Dijon, France.
Julie VincentDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Sylvia IlieDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Caroline TruntzerUniversity Bourgogne Franche-Comté, Dijon, France.
François Ghiringhelli *University Bourgogne Franche-Comté, Dijon, France. fghiringhelli@cgfl.fr.
Marion Thibaudin *University Bourgogne Franche-Comté, Dijon, France. mthibaudin@cgfl.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is a primary brain tumor with a dismal prognosis, often resistant to immunotherapy and associated with immune suppression. This study aimed to assess the impact of steroids and Stupp-regimen treatment on peripheral blood immune parameters in GBM patients and their association with outcomes.

methodsUsing cytometry panels and bioplex assays, we analyzed the immune phenotype and serum cytokines of 54 GBM patients and 21 healthy volunteers.

resultsGBM patients exhibited decreased lymphoid cell numbers (CD4, CD8 T cells, NKT cells) with heightened immune checkpoint expression and increased myeloid cell numbers (especially neutrophils), along with elevated pro-inflammatory cytokine levels. Steroid use decreased T and NK cell numbers, while radio-chemotherapy led to decreased lymphoid cell numbers, increased myeloid cell numbers, and heightened immune checkpoint expression. Certain immune cell subsets were identified as potential outcome predictors.

conclusionOverall, these findings shed light on the peripheral immune landscape in GBM, emphasizing the immunosuppressive effects of treatment. Baseline immune parameters may serve as prognostic indicators for treatment response.

Indexed as

Brain NeoplasmsChemoradiotherapyGlioblastomaAdultAgedCytokinesFemaleHumansMaleMiddle AgedPrognosisCytokinesBiomarkerGlioblastomaImmune responseSteroidTemozolomide

Identifiers

PMID38753169
PMCPMC11098987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.